Cargando…
Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387295/ https://www.ncbi.nlm.nih.gov/pubmed/32071430 http://dx.doi.org/10.1038/s41375-020-0749-5 |
| _version_ | 1783564092030582784 |
|---|---|
| author | Burke, G. A. Amos Beishuizen, Auke Bhojwani, Deepa Burkhardt, Birgit Minard-Colin, Véronique Norris, Robin E. Kabickova, Edita Pinarli, F. Guclu Tacyildiz, Nurdan Howes, Angela Jong, Jan de Liu, Grace Nottage, Kerri Salman, Mariya Trixhe, Xavier Woot de Cairo, Mitchell |
| author_facet | Burke, G. A. Amos Beishuizen, Auke Bhojwani, Deepa Burkhardt, Birgit Minard-Colin, Véronique Norris, Robin E. Kabickova, Edita Pinarli, F. Guclu Tacyildiz, Nurdan Howes, Angela Jong, Jan de Liu, Grace Nottage, Kerri Salman, Mariya Trixhe, Xavier Woot de Cairo, Mitchell |
| author_sort | Burke, G. A. Amos |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7387295 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-73872952020-08-11 Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy Burke, G. A. Amos Beishuizen, Auke Bhojwani, Deepa Burkhardt, Birgit Minard-Colin, Véronique Norris, Robin E. Kabickova, Edita Pinarli, F. Guclu Tacyildiz, Nurdan Howes, Angela Jong, Jan de Liu, Grace Nottage, Kerri Salman, Mariya Trixhe, Xavier Woot de Cairo, Mitchell Leukemia Correspondence Nature Publishing Group UK 2020-02-18 2020 /pmc/articles/PMC7387295/ /pubmed/32071430 http://dx.doi.org/10.1038/s41375-020-0749-5 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Correspondence Burke, G. A. Amos Beishuizen, Auke Bhojwani, Deepa Burkhardt, Birgit Minard-Colin, Véronique Norris, Robin E. Kabickova, Edita Pinarli, F. Guclu Tacyildiz, Nurdan Howes, Angela Jong, Jan de Liu, Grace Nottage, Kerri Salman, Mariya Trixhe, Xavier Woot de Cairo, Mitchell Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy |
| title | Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy |
| title_full | Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy |
| title_fullStr | Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy |
| title_full_unstemmed | Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy |
| title_short | Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy |
| title_sort | ibrutinib plus cit for r/r mature b-nhl in children (sparkle trial): initial safety, pharmacokinetics, and efficacy |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387295/ https://www.ncbi.nlm.nih.gov/pubmed/32071430 http://dx.doi.org/10.1038/s41375-020-0749-5 |
| work_keys_str_mv | AT burkegaamos ibrutinibpluscitforrrmaturebnhlinchildrensparkletrialinitialsafetypharmacokineticsandefficacy AT beishuizenauke ibrutinibpluscitforrrmaturebnhlinchildrensparkletrialinitialsafetypharmacokineticsandefficacy AT bhojwanideepa ibrutinibpluscitforrrmaturebnhlinchildrensparkletrialinitialsafetypharmacokineticsandefficacy AT burkhardtbirgit ibrutinibpluscitforrrmaturebnhlinchildrensparkletrialinitialsafetypharmacokineticsandefficacy AT minardcolinveronique ibrutinibpluscitforrrmaturebnhlinchildrensparkletrialinitialsafetypharmacokineticsandefficacy AT norrisrobine ibrutinibpluscitforrrmaturebnhlinchildrensparkletrialinitialsafetypharmacokineticsandefficacy AT kabickovaedita ibrutinibpluscitforrrmaturebnhlinchildrensparkletrialinitialsafetypharmacokineticsandefficacy AT pinarlifguclu ibrutinibpluscitforrrmaturebnhlinchildrensparkletrialinitialsafetypharmacokineticsandefficacy AT tacyildiznurdan ibrutinibpluscitforrrmaturebnhlinchildrensparkletrialinitialsafetypharmacokineticsandefficacy AT howesangela ibrutinibpluscitforrrmaturebnhlinchildrensparkletrialinitialsafetypharmacokineticsandefficacy AT jongjande ibrutinibpluscitforrrmaturebnhlinchildrensparkletrialinitialsafetypharmacokineticsandefficacy AT liugrace ibrutinibpluscitforrrmaturebnhlinchildrensparkletrialinitialsafetypharmacokineticsandefficacy AT nottagekerri ibrutinibpluscitforrrmaturebnhlinchildrensparkletrialinitialsafetypharmacokineticsandefficacy AT salmanmariya ibrutinibpluscitforrrmaturebnhlinchildrensparkletrialinitialsafetypharmacokineticsandefficacy AT trixhexavierwootde ibrutinibpluscitforrrmaturebnhlinchildrensparkletrialinitialsafetypharmacokineticsandefficacy AT cairomitchell ibrutinibpluscitforrrmaturebnhlinchildrensparkletrialinitialsafetypharmacokineticsandefficacy |